https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-92013-08-01 00:00:002019-02-15 08:50:01Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-13 / Ann. Surg. Oncol. 2013 Oct;20(10):3233-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-13 / Ann. Surg. Oncol. 2013 Oct;20(10):3233-92013-07-13 00:00:002019-02-15 08:50:02Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / Radiother Oncol 2013 Nov;109(2):188-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / Radiother Oncol 2013 Nov;109(2):188-932013-06-03 00:00:002013-06-03 00:00:00Re-irradiation and hyperthermia after surgery for recurrent breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-832012-12-11 00:00:002012-12-11 00:00:00Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-92012-11-01 00:00:002012-11-01 00:00:00[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-242012-09-01 00:00:002023-03-07 13:03:07Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-26 / Braz. J. Med. Biol. Res. 2012 Jun;45(6):510-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-26 / Braz. J. Med. Biol. Res. 2012 Jun;45(6):510-52012-04-26 00:00:002019-02-15 08:50:04Co-culture of apoptotic breast cancer cells with immature dendritic cells: a novel approach for DC-based vaccination in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R392012-03-07 00:00:002019-02-15 08:50:03Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-17 / Cancer 2012 Sep;118(17):4354-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-17 / Cancer 2012 Sep;118(17):4354-622012-01-17 00:00:002023-03-07 13:04:41HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ